Overview

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

Status:
Not yet recruiting
Trial end date:
2027-12-27
Target enrollment:
Participant gender:
Summary
The main objective of the study is to evaluate the efficacy of satralizumab compared with placebo based on time from randomization to the first occurrence of an adjudicated MOGAD relapse in the double-blind (DB) treatment period
Phase:
Phase 3
Details
Lead Sponsor:
Hoffmann-La Roche